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Abstract
Molecular profiling of DNA and RNA has provided valuable new insights into the genetic basis of non-malignant
and malignant disorders, as well as an increased understanding of basic mechanisms that regulate human disease.
Recent technological advances have enabled the analyses of alterations in gene-based structure or function in a
comprehensive, high-throughput fashion showing that each tumor type typically exhibits distinct constellations of
genetic alterations targeting one or more key cellular pathways that regulate cell growth and proliferation, evasion
of the immune system, and other aspects of cancer behavior. These advances have important implications for
future research and clinical practice in areas as molecular diagnostics, the implementation of gene or pathway-
directed targeted therapy, and the use of such information to drive drug discovery. The 1st international and 32nd
Annual Conference of Italian Association of Cell Cultures (AICC) conference wanted to offer the opportunity to
match technological solutions and clinical needs in the era of precision medicine.
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Presentation of the conference
The 1st international and 32nd Annual Conference of
AICC was held at Magna Graecia University Campus S.
Venuta, Catanzaro, on October 1st-2nd, 2019 with the
Scientific Coordination of Dr. Maria Teresa Di Martino,
from the same Academia. The conference was inaugu-
rated by Prof. Michele Caraglia, President of the AICC.
From circulating biomarkers, to mutational, transcripto-
mics and immunomics landscape, the meeting described
a panorama of new platforms for personalization of ther-
apy. This year conference also was an attempt to
internationalize the traditional AICC annual conference,
via the participation of internationally renewed Italian
scientists and speakers coming from foreign countries,
including the Nobel prize winner Bruce Alan Beutler,
determining the success of the Conference. The orga-
nizers deeply thank those who took part in the confer-
ence and made it a success.
Opening ceremony
The opening ceremony involved the academics author-
ities together with Prof. Beutler, Nobel Prize in Physi-
ology or Medicine 2011, from University of Texas
Southwestern Medical Center, Dallas (USA), who held a
keynote lecture entitled “Inducing phenotypes, discover-
ing them, and instantly solving them”. Prof. Beutler is
the Director of the Center for the Genetics of Host
Defense, and since its establishment Beutler’s team have
produced nearly half a million of induced mouse germ-
line mutations, covering almost all the models freely
available for scientific use. Beutler is a pioneer in the
study of innate immunity, and he was rewarded with the
Nobel Prize for the discovery of the elusive sensing
mechanism by which host cells recognize pathogens.
Beutler spoke about the 25-years old challenge to find
the receptor for lipopolysaccharide (LPS), also known as
endotoxin, and about how he became interested in the
question during the ‘80s, when he purified mouse tumor
necrosis factor (TNF) and demonstrated that it was a
key executor of LPS toxicity (systemic inflammation and
death from septic shock). At that point, he began to
wonder what the LPS receptor was, and therefore, how
were microbes sensed by cells of the innate immune
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system. During his studies, Beutler used many methods
in an attempt to find the LPS receptor, but ultimately
only genetics led to a solution. By the use of C3H/HeJ
and C57BL/10ScCr mice, carrying mutations of the LPS
gene, in 1998 Beutler demonstrated that one of the
mammalian Toll-like receptors, TLR4, acts as the
membrane-spanning component of the mammalian LPS
receptor complex [1]. In fact, he showed that destructive
mutations of Tlr4 gene predispose to the development
of Gram-negative sepsis, while leaving most aspects of
immune function intact. The long path of the positional
cloning research concluded with the discovery of TLRs
won him the Nobel Prize in 2011.
While in the ‘90s it took him several years to track
down a new gene, in the new millennium Beutler’s lab
employed a new approach, based on “forward genetics”,
to identify new genes involved in mammals’ immunity.
In these studies, using the mutagen agent N-ethyl-N-
nitrosourea (ENU), Beutler’s laboratory randomly gener-
ated a number of germline mutations in mouse models,
detected about 200 mutations altering innate immune
response and finally isolated them by positional cloning.
Furthemore, by using the Linkage Explorer tool, Beu-
tler’s team identifies the causative mutations among all
candidate “phenotypic mutations” by browsing ENU-
induced mutations and phenotypic effects. As multiple
alleles of genes are acquired through mutagenesis,
pooled “superpedigrees” are created to analyze the ef-
fects of mutations, automatically generated and analyzed
by Linkage Analyzer [2]. This method has different ad-
vantages with respect to the conventional forward gen-
etic methods, such as the unbiased declaration of
mappable phenotypes, including those that are incom-
pletely penetrant, the automated identification of causa-
tive mutations concurrent with phenotypic screening,
the exclusion of genes not involved in phenotypes of
interest. Notably, when phenotypic data are uploaded,
the genetic cause of any phenovariance that may exist in
the dataset is usually known within a few minutes.
Through the discovery of genes necessary for a par-
ticular process, Beutler’s lab continues gaining insight
into the mechanism of a specific process and begins to
understand the roles of individual genes. A full under-
standing of gene function forms the basis for developing
effective treatments for human disease. Against this
backdrop of growing knowledge, Beutler’s lab seeks to
identify novel drugs and drug targets that may provide
new strategies to treat diseases.
Further along the conference, a distinguished lecture was
held by Michele Carbone, from University of Hawaii, in
Honolulu (USA), with the title “The BAP1 cancer syn-
drome: unique mechanisms and clinical characteristics re-
quiring specific medical approaches”. This is a very exciting
story running from approximately 25 years regarding the
discovery of BAP1 mutations that define a novel cancer
syndrome. Mesothelioma is caused predominantly by occu-
pational or environmental exposure to asbestos and to
other carcinogenic fibers and its incidence has decreased in
Australia, USA, and Western Europe, where the use of as-
bestos has been rigorously regulated in the 1970s and
1980s, demonstrating the value of these preventive mea-
sures. In developing countries however, where large
amounts of asbestos are still used, the overall mesothelioma
mortality has not decreased; moreover, carcinogenic fibers
are present in the environment and are disturbed as rural
areas are being developed. Carbone, following his studies in
Cappadocia, postulated that the epidemic mesothelioma
observed in 3 villages of the area could not be attributed
merely to erionite exposure, present in higher amounts in
this environment, because only some families had meso-
thelioma cases in their pedigree despite sharing the same
living environment. To shed light on this aspect, in 2001
Carbone’s team begun to study two US families affected by
mesothelioma without a story of environmental exposure
to carcinogenic fibers and demonstrated that all affected
family members carried inherited germline mutations of
the BAP1 gene. Germline BAP1 mutations-affected family
members developed multiple malignancies, predominantly
mesotheliomas and uveal melanomas, and less frequently
skin melanomas and other tumors. Moreover, the discovery
that individuals affected by the BAP1 cancer syndrome may
develop benign melanocytic BAP1-mutated atypical intra-
dermal tumors (MBAITs) provides an early marker to iden-
tify individuals at high risk of developing associated cancers
[3]. In addition, Carbone’s group demonstrated that ap-
proximately 60% of mesotheliomas acquired BAP1 somatic
mutation during tumor cell growth, underscoring the crit-
ical role of BAP1 in preventing mesothelioma growth.
BAP1 is a deubiquitylase that modulates the activity of mul-
tiple genes and proteins involved in DNA replication, DNA
repair, metabolism, and cell death, and has a strong tumor
suppressor activity [4]. In particular, Carbone showed that
BAP1 regulates both DNA repair and apoptosis as a result
of DNA damage caused by asbestos, ultraviolet light, radi-
ation, or chemotherapy. In fact, BAP-1 mutation inhibits
asbestos-induced cell death, ensuring the viability of can-
cerogenic clones. In the cytoplasm, BAP1 modulates the
stability of the IP3R3 channel, which allows the flux of Ca2+
from the endoplasmic reticulum into the mitochondria,
where Ca2+ is required for the Krebs cycle and, at higher
doses, promote cytochrome c release favouring apoptosis.
As a consequence, reduced BAP1 levels in “normal” cells
induce a Warburg effect, i.e., a shift from oxidative phos-
phorylation to aerobic glycolysis, a process that might
prime these “normal” cells for malignant transformation
and tumor growth. Therefore, high incidence of cancers in
BAP1+/− carriers results from the combined reduced nu-
clear and cytoplasmic BAP1 activities (Fig. 1).
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Current therapies extend the survival of mesothelioma
patients only to ~ 1 year [6], whereas carriers of germline
BAP1 mutations have an average survival of 5 years, an
amount of time that significantly exceeded the benefit of
any currently available therapy, thus suggesting that
germline BAP1 mutations could be exploited as a prog-
nostic factor [5, 7, 8]. The clinical translation of this dis-
covery is the possibility to perform genotyping of
patients and their relatives to identify carriers of germ-
line mutations for screening programs and to conduct
genomic studies on tumor biopsies to identify actionable
mutations.
SESSION I. Biomarkers for diagnosis, monitoring of
progression and therapeutic response
Giuseppe Novelli from Tor Vergata University in Rome
(Italy), held the first presentation of the session, focused on
the use of biomarkers for the diagnosis, monitoring and
therapeutic response of diseases. Non-communicable dis-
eases (NCD) are chronic conditions such as diabetes, ath-
erosclerosis, ischemia, heart attack, respiratory infections
and tumors. Initially, a problem only for advanced coun-
tries, in recent years they have become among the main
causes of death on the planet. These diseases are the result
of complex interactions between economic growth, devel-
opment, population aging, environmental changes and
lifestyle.
To counteract the activation of mechanisms that can
lead to the development of chronic diseases, it is essen-
tial to generate an innovative and personalized model of
care. Translational genomics is the union of genetic re-
search applied to the clinic passing through an in-depth
analysis of results and digital innovation. Studies on the
genetics of complex diseases pass through the improve-
ment of available therapies avoiding individuals who
could develop adverse events. To obtain reproducible re-
sults, it needs genetic studies that can identify which
components of the measures are heritable and which are
predictable need. Therefore, by studying and identifying
genetic variants that influence pharmacokinetics, it is
possible to formulate prognostic biomarkers able to
identify the response to drugs in individuals, in order to
Fig. 1 BAP-1 modulates DNA repair and Ca++ levels. Increased DNA damage is observed in BAP-1 mutant cells (BAP-1+/−, −/−) after exposure to
asbestos, ultraviolet light, radiation, and chemotherapy as well as in cells with reduced BAP1 levels by siRNA experiments. In the nucleus, BAP-1
regulates DNA repair. In the cytoplasm, BAP-1 stabilizes by deubiquitylation (Ub) the IP3R3 receptor channel that in turn regulates Ca++ transfer
from the endoplasmic reticulum (ER), in which Ca++ is normally stored, to the cytoplasm. Calcium ions, released from the ER, flow through the
voltage-dependent anion channel (VDAC) located on the outer mitochondrial membrane, and then are actively transported inside the
mitochondria by the mitochondrial uniporter channel complex (MCU) located on the inner mitochondrial membrane. Here, Ca++ is required for
the normal activity of the Krebs’ cycle. In BAP-1+/−, −/− cells, reduced Ca++ concentrations impair mitochondrial respiration (Krebs cycle), and the
cells switch to aerobic glycolysis (Warburg effect). Moreover, in normal cells (BAP-1+/+), following a DNA damage that cannot be repaired, higher
amounts of calcium ions are released from the ER and the consequently higher mitochondrial Ca++ concentration, causes the release of
cytochrome c from mitochondria into the cytosol, thus starting the apoptotic cascade. In contrast, BAP-1 mutated cells, in which an insufficient
amount of Ca++ is released, cannot start the apoptosis process, therefore the mutated cells are able to divide and may give rise to malignancy.
Cartoon adapted from Carbone et al. [5]
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carry out interventions and select therapeutic targets.
Advances in whole-genome sequencing that identify
genes involved in many diseases facilitate susceptibility
to therapeutic treatment. Continuous identification of
new genes and biomarkers specific to subtypes disease is
essential for translation into personalized medicine [9].
The development of biomarkers to improve diagnosis,
identify disease progression and patients who are more
likely to respond to treatment, lead to a better risk strati-
fication and facilitate decision-making in the clinical
setting.
Overall, specific tumor mutations are identified followed
by the synthesis of new antigens (peptides, miRNAs) or
collections of platforms combined according to the indi-
vidual’s tumor model [10]. Circulating miRNAs are as-
sumed as excellent biomarkers for cancer as they regulate
gene expression and are involved in cancer activation and
development. To date the use of biological therapies for
severe psoriasis can be effective for some patients but the
therapeutic response can vary according to drug. The
HLA-C*06:02 status has identified as a predictive bio-
marker that influence the response to most commonly
used biologic treatments for psoriasis. The main reason to
address personalized medicine approaches is to identify
and treat only those patients who have a high potential to
benefit from a particular therapy [11].
Currently only one biomarker is determined to guide
the treatment, future molecular diagnostics may provide
a simultaneous comprehensive profiling of multiple
markers (multiplex testing). This means a movement
from a single marker to a signature, and in the case of
functional tumor profiling, this will allow us to select the
most effective combination therapy for each patient.
Francesco Pepe from University Federico II of Naples
(Italy), presented advances on evolution of liquid biopsy
in oncology. During tumor progression, a strong select-
ive pressure leads to the formation of resistant clones
that proliferate rapidly and are less sensitive to drug
treatment. To understand the molecular vision of solid
tumors, biopsy samples are used, but unfortunately,
sampling can often be damaged, limited in quantity and
only partially highlights the heterogeneity of the entire
tumor mass. Various studies have shown that the genetic
profiles of tumor DNA obtained from cell-free DNA
(cfDNA) and circulating tumor cells (CTC) strongly cor-
respond to those of the tumor of origin [12]. This dis-
covery has had important consequences both in
molecular pathology and in clinical oncology.
Liquid biopsies are a multitude of minimally invasive
techniques that can enable a real-time biomolecular
characterization of the tumor through the analysis of hu-
man blood and other biological fluids such as urine, sal-
iva, pleural effusions and cerebrospinal fluid [13]. In
particular, circulating nucleic acids (ctDNA) are used to
assess the response to a treatment that can normally in-
duce drug resistance and even be able to assess the
slightest residual disease [14].
In non-small cell lung cancer (NSCLC), very often,
there is a poor availability of biopsies and cytological
samples for immuno-histochemical and molecular ana-
lysis. This makes the use of liquid biopsies very attract-
ive. For example, the analysis of the molecular state of
the epidermal growth factor receptor (EGFR) by means
of tumor ctDNA, extracted from plasma, is a valid alter-
native to tissues, in order to evaluate the suitability of
patients for the administration of tyrosine kinase inhibi-
tors (TKIs). The development of the next-generation se-
quencing method (NGS) allows the simultaneous
evaluation of multiple somatic mutations. In addition to
the hybrid capture technique, it is also possible to deter-
mine the presence of other genetic alterations, such as
fusions. This approach achieved a marked increase in
the detection of therapeutically targetable mutations.
Pepe showed some results obtained by SiRe, a panel
which covers 568 mutations in six genes (EGFR, KRAS,
NRAS, BRAF, cKIT and PDGFRa) involved in NSCLC,
gastrointestinal stromal tumor, colorectal carcinoma and
melanoma [15]. It is interesting to note that out of a
total of 322 NSCLC samples analyzed, only 28 (8.7%)
failed to produce an adequate library, thus demonstrat-
ing the high performance of SiRe analytical parameters.
Interestingly, the EGFR TKIs treatment based on SiRe
genotyping lead to a clinical benefit in 82% of NSCLC
patients thus highlighting the relevance of this tool for
clinical application. Furthermore, recent advances in the
technique of liquid biopsy have identified EML4-ALK
translocation in the exosomal load (ExoALK) in NSCLC
patients as a possible biomarker for the diagnosis and
prognosis of this disease. The next perspectives will in-
clude early diagnosis and monitoring of the clinical
benefit of drug treatment.
SESSION II. Single cell profiling: from bench to bedside
The constant interaction between tumor microenviron-
ment (TME) and infiltrating cells as a driving factor affect-
ing tumor progression or immuno-surveillance was the fil
rouge of the second session. Tumor evolution is indeed
controlled by a fine balance between the decrease in ef-
fector cells (such as CD8+ T-lymphocytes, natural killer –
NK – cells, M1-polarized tumor-associated macrophages,
TAMs), endorsed by anti-tumor activity, and the increase
in immuno-suppressive cells (such as T-regulatory – Treg
- cells, myeloid-derived suppressor cells – MDSCs -, M2-
polarized TAMs), characterized by a tumor-tolerant
phenotype [16]. Specific oncogenic pathways activated in
solid tumors, such as β-catenin pathway [17], often dictate
the type and activity of immuno-infiltrating cells, tipping
the balance between an effective control of tumor
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progression by the host immune system and a tumor-
induced immuno-suppression. The tumor mutation bur-
den is also critical: indeed it is well recognized in colon,
breast and pancreatic ductal adenocarcinoma (PDAC) that
higher is the mutation burden, higher is the spectrum of
neoantigens generated and the possibility of inducing
immuno-surveillance rather than immune-evasion [18].
Not only genetic alterations, but also epigenetic changes
play a role in this balance.
In this second session, with an elegant series of experi-
ments, Renato Ostuni, from San Raffaele Telethon Insti-
tute for Gene Therapy (SR-Tiget), Milano, Italy, unveiled
an unexpected integration between inflammatory and
immuno-suppressive stimuli on TAMs of PDAC. Indeed,
in a complex inflammatory environment as TME, TAMs
are exposed simultaneously to different cytokines, each
activating completely different transcriptional and epi-
genetic programs. For instance, the concomitant expos-
ure of macrophages to IL-4 and IFN-γ produced an
antagonistic response, because IFN-γ inhibits the tran-
scriptional and epigenetic programs induced by IL-4.
Manipulating the ratio between the two cytokines re-
verses the resistance to IL-4, changing the macrophages
activation [19]. In the context of PDAC, Ostuni groups’
highlighted that TAMs epigenetically up- or down-
regulate the expression of inflammatory-related genes in
response to different cytokine, alone or in combination.
These changes linking the pro-inflammatory/immuno-
suppressive signal of TME to the epigenetic reprogram-
ming determine the fate of TAM in terms of
polarization, pro-tumor or anti-tumor activities. Amaz-
ingly, the changes in epigenetic programs can be
followed at single cell level. These observations indicate
that TAMs are endorsed by a huge plasticity and hetero-
geneity [20], as already reported for other immuno-
infiltrating populations such as neutrophils [21]. If such
plasticity of TAMs and immuno-infiltrating cells justifies
the high variability of responses to immuno-therapy, it
should also be considered as the premise for a new treat-
ment approach for PDAC, a tumor poorly responsive to
chemotherapy and immuno-therapy. Indeed, a broad
spectrum of immuno-modulators, ranging from cyto-
kines to bacterial products such as LPS, may be used to
reprogram TAMs at single cell level, forcing pro-tumor
cells to become anti-tumor effectors. The work
presented by Ostuni paves the way to a “precision
immuno-therapy”, that could be a promising approach
to counteract the progression of PDAC and of other
cancers characterized by a strong immuno-evasive/
immuno-suppressive phenotype.
Precision medicine is now a realistic vision in medical
oncology but tumor cell heterogeneity represents a sub-
stantial hurdle, so the knowledge of the variations in
tumor morphology, genetic or proteomic expression,
might provide informations on the intra- and inter-
tumor diversity and potentially on how the tumor cells
might respond to treatment [22]. Tumor heterogeneity
is frequently seen as the result of genetic evolution but
additional mechanisms such as epigenetic modifications,
transcriptional changes and alterations in protein levels
or protein modifications in the tumor cells and/or the
microenvironment also play a major role [23]. With the
recent advances in technologies for single-cell analysis
made during the past years, it is possible to monitor dy-
namic changes in tumor heterogeneity at genomic, tran-
scriptomic, proteomic and functional levels.
In this context, Alice Giustacchini from Institute of
Child Health in London (UK) reported a novel method
to characterize cancer stem cells from Chronic Myeloid
Leukemia (CML) patients who progressed after therapy
with TKIs. CML is a clonal myeloproliferative disorder
characterized by a chromosome translocation that gen-
erates the BCR-ABL oncogene encoding a constitutive
kinase activity. Despite the high efficacy of TKIs which
lead to the remission of disease, a high proportion of pa-
tients relapsed and this is the result of the propagation
of CML stem cells (CML-SCs) which developed resist-
ance to TKIs [24]. By combining single-cell RNA se-
quencing and high sensitivity targeted mutation
detection, Giustacchini’s group developed a BCR-ABL-
targeted Smart-seq-2 protocol (BCR-ABL tSS2) to study
CML-SCs heterogeneity and to identify the signatures of
these cells from diagnosis through remission post-TKIs
administration and relapse. In particular, this strategy
permitted to distinguish BCR-ABL+SCs and BCR-ABL−
SCs cells from normal hematopoietic stem cells (HSCs)
and to analyze whole transcriptome with a highly spe-
cific and quantitative result in the single cell, at diagno-
sis, in the course of therapy with TKIs and at relapse
with blast crisis progression (Fig. 2). Interestingly, they
observed heterogeneity in BCR-ABL− SCs with a distinct
cluster already detected at diagnosis and the presence of
this population was predictive of poor response as these
patients later lacked to achieve major molecular re-
sponse. An enriched expression of IL-6 associated genes
and STAT5, accompanied by increased expression of
genes involved in in TGF-β and TNF-α pathways, associ-
ated with increased SC quiescence, was reported in the
BCR-ABL− SCs and this observation correlates with the
elevated serum levels of TNF-α and TGF-α in patient
elicited poor response to treatment [25]. TGF-α and IL-
6 plasma levels selectively identify CML patients who
failed to achieve an early molecular response or progress
in the first year of therapy. Moreover, Giustacchini re-
ported the presence of rare persisting BCR-ABL+SCs in
patient in the course of remission, already present at the
diagnosis but enriched in highly quiescent cells. A tran-
scriptionally pattern distinct from quiescent normal
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hematopoietic SCs was observed in BCR-ABL+SCs with
activation of TGF-β and TNF-α pathways, representing
possible targets for a new therapeutic combinatorial in
CML. In summary, single-cell transcriptomic with high
sensitivity detection of mutations provide insights into
cellular and molecular mechanisms of resistance of
CML-SCs to therapy and could be useful for predicting
and monitoring therapy response and for the identifica-
tion of new and more effective treatment to improve
clinical outcome of this disease [26].
SESSION III. Functional genomics in clinical practice
In recent years, the great progress in the development of
methods for massive sequencing of large number of gen-
omic sequences, termed NGS, has led to the accumula-
tion of an incredible amount of data that can be used for
a number of diagnostics, prognostic and therapeutic ap-
proaches, now approved for clinical purposes [27]. One
of the main challenges in the use of such amount of data
is the need to annotate genomic regions with their bio-
logical functions, associating molecular phenotypes to
specific mutations in coding or non-coding sequences.
This process is often classified as functional genomics
and exploits different strategies based on genomic and
transcriptomic protocols to identify new potential targets
for applications in clinical practice.
In this context, Daniele Caracciolo from the Magna
Graecia University, Catanzaro (Italy) reported data that
highlight the relevance of genomic instability in multiple
myeloma (MM), which is characterized by the presence
of plasma cells harboring numerous and progressive
karyotypic aberrations. Indeed, previous data have
highlighted mutation or deletion of genes implicated in
DNA damage response in 22% of MM patients [28]. Fur-
ther investigations by Caracciolo and coworkers have
provided evidence that increased expression of the DNA
ligase III (LIG3) correlates with worst prognosis in MM
and is crucial for genomic instability and survival of
multiple myeloma cells. LIG3 plays a fundamental role
in Alternative Non Homologous End Joining (Alt-NHEJ)
repair, which may be a cause for genomic instability. In-
deed, increased LIG3 mRNA expression in multiple
myeloma patients correlates with shorter survival and
with more advanced stage of disease [29].
Interestingly, experiments performed by Caracciolo
and coworkers have shown that knockdown of LIG3 re-
duces MM cells viability, suggesting that neoplastic
plasma cells are dependent on LIG3-driven repair. This
observation has prompted the search for new potential
LIG3 inhibitors, useful for clinical application, which is
still in progress. Investigation of the post-transcriptional
mechanism of regulation of LIG3, has led to the identifi-
cation of miR-22-3p as a negative regulator of LIG3.
Fig. 2 Single-cell transcriptomic of Chronic Myeloid Leukaemia Stem Cells (CML-SCs). The simultaneous single-cell mutation detection and RNA
sequencing obtained by the novel BCR-ABL-targeted Smart-seq-2 protocol (BCR-ABL tSS2) permitted to study CML-SCs heterogeneity and to
identify a subpopulation of resistant SCs, otherwise not possible through cell-population analysis. This approach allows to identify in resistant cells
a number of dysregulation in genes and pathways which could be useful to predict disease response to therapy and targeted for
precision medicine
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Enforced expression of miR-22 in MM cells effectively
downregulated LIG3 protein, which in turn increased
DNA damage, to a level that inhibited in vitro and
in vivo cell growth, inducing apoptotic cell death [29].
Further unpublished data by Caracciolo and coworkers
show the involvement of Myc in the transcriptional
regulation of Lig3, miR-22 and PARP1, prompting the
identification of another mechanism through which Myc
plays a role in MM tumorigenesis [Unpublished data].
Giovanni Tonon, from the Center for Translational
Genomics and Bioinformatics, San Raffaele Scientific In-
stitute, Milan (Italy), again digging from data obtained in
MM genome sequencing, focused on DIS3, a 3′-5′ exor-
ibonuclease which is mutated in up to 18% of MM pa-
tients. DIS3 is the catalytic core of the RNA exosome,
involved in turnover of normal mRNAs, maturation of
precursor RNAs and RNA quality control (degradation
of aberrant RNA precursors, control of mRNA expres-
sion levels, degradation of promoter upstream tran-
scripts). Tonon demonstrates that DIS3 depleted cells
show widespread increase of DNA:RNA hybrids, ending
in an increased genomic instability, thus suggesting that
DIS3 is also engaged in DNA damage response, in par-
ticular in the NHEJ repair. Indeed, loss of DIS3 increases
DNA:RNA hybrids and impairs DSB repair, inducing a
BRCAness status and accumulation of mutations. MM
samples analysis has confirmed that DIS3 mutated tu-
mors present higher mutational burden, associated with
an interferon I response [30]. Furthermore, Tonon has
provided an essential contribution to the topic of tumor
resistance to treatments: tumors cells may exhibit a re-
versible drug-tolerance, induced by epigenetic changes
in phenotypically distinct subpopulations of cells, which
allows survival of the tumor and further tumor evolution
and progression after the initial elimination of the tumor
bulk and suspension of the treatment. This phenomenon
highlights the need for single cell analysis and study of
single cell cancer evolution in the clinic. Dissection of
the modifications undergone by tumor cells after the ini-
tial drug treatment allows the identification of different
pattern of expressions and genomic alterations, that may
be due to the formation of extrachromosomal circular
DNA (eccDNA), double minutes, which provides a dif-
ferent genotype/phenotype, favouring cancer evolution.
Andrea Mafficini, from the ARC-Net Centre for ap-
plied research on cancer and the Department of Diag-
nostics and Public Health, University and Hospital Trust
of Verona (Italy), has presented data on the genomic
landscape of PDAC. These tumors include well-
differentiated Pancreatic Neuroendocrine Tumors (Pan-
NETs), featuring a variable prognosis from indolent to
aggressive, and poorly differentiated Pancreatic Neuro-
endocrine carcinomas (PanNEC), which show a worst
prognosis like that of PDAC. PanNETs and PanNEC
differ also in term of genetic alterations being PanNEC
genetically characterized by TP53 and RB1 inactivation
while PanNETs are more heterogeneous. Mafficini
underlined that the current challenge is to identify signa-
ture for actionable pathways for these rare tumors. Maf-
ficini summarized several sets of potential targets,
including Wnt pathway, cell cycle regulation, PI3K/
mTOR, Chromatin remodeling, homologous recombin-
ation and DNA single base repairs [31]. Mafficini also il-
lustrated the Master registry trial in which samples from
patients with rare tumors without curative options were
explored by whole genome sequencing and RNAseq.
Based on molecular profiling and clinical interpretation
of molecular data by a molecular tumor board, were sug-
gested indications of genomics-guided treatment, with
evidences of relevant improvement of response in several
cases. The possibility that a comprehensive gene panel
may be a better choice for the identification of the genes
that matter the most. Unfortunately, most commercial
and custom cancer panels show poor concordance in
gene selection, likely due to lack of objective methodolo-
gies, and most panels lack of adequate coverage of struc-
tural variants, which are the majority of clinically
informative data. To this end, the International Cancer
Genome Consortium has the goal to obtain a compre-
hensive description of genomic, transcriptomic and epi-
genomic changes in 50 different tumor types or subtypes
[32]. Another issue highlighted by ultradeep sequencing
is the intratumor heterogeneity, and the presence of low
abundance mutations which may confer clonal resist-
ance to therapy. These large-scale data allowed to place
previous findings in a more defined frame and provided
potential markers for patient stratification and compan-
ion diagnostics.
Finally in this session, Javier De Las Rivas, from the
Grupo de Investigacion en Bioinformatica y Genomica
Funcional Cancer Research Center (CiC-IBMCC, CSIC/
USAL/IBSAL), Consejo Superior de Investigaciones
Científicas and University of Salamanca, Salamanca
(Spain), talked about the analysis of cancer genomic data
in order to achieve better patient stratification and per-
sonalized molecular profiling. Javier De Las Rivas under-
lined that cancer is not a genetic disease affecting only
one or few genes, but instead it is a “genomic disease” in
which many genes are involved. Moreover, differences in
the panel of genes involved are not only from different
type of cancer, but also in each patient and at different
stages of the disease. Indeed, De Las Rivas discussed the
great difficulty to know in the processes of identifying
biomarkers for specific individuals or subtype of tu-
mours. The application of omic technologies in cancer
research lead to the generation of thousands of data that
can only be useful if advanced computational and statis-
tical methods are available for their analysis. De Las
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Rivas’ group developed this type of methods, including
the DECO method (decomposing heterogeneous cohorts
using omics data profiling) [33]. This new method allows
to find significant association between biological features
(biomarkers) and samples in large scale omics data.
DECO greatly enhances the discovery of biomarkers,
and the accurate patient stratification. They also de-
scribed a robust strategy to combine transcriptomic ex-
pression data with patient survival data. The appropriate
integration of omic and survival clinical data is a neces-
sary step to build risk predictors and apply these predic-
tors to the prognosis of patients.
At the end of this session a distinguished lecture was held
by Gerry Melino, from Medical Research Council, Toxicol-
ogy Unit, Cambridge (UK), with title “ZNF281 contributes
to the DNA damage response and is a prognostic maker for
neuroblastoma”. He illustrated the recent results obtained in
his lab supporting the opportunities for cancer patients’
stratification and for the development of personalized thera-
peutic strategies. ZNF281 is a zinc-finger factor affecting cell
death, which expression increases after genotoxic stress
caused by DNA-damaging drugs. ZNF281 silencing signifi-
cantly increases cell death upon chemotherapy in vitro by
regulating XRCC2 and XRCC4, two genes that take part in
homologous recombination and non-homologous end join-
ing, respectively [34]. Both are transcriptionally activated by
ZNF281 through a DNA-binding-dependent mechanism,
involving an interaction with c-Myc. Conversely, ZNF281
decreases during neuronal differentiation of embryonic stem
cells and in retinoic acid-induced differentiation of neuro-
blastoma (NB) cells. Silencing of ZNF281 induces neuronal
differentiation of NB cells while its ectopic expression causes
the opposite effect. Furthermore, the expression of ZNF281
is inhibited by TAp73 through miR-34a. Contrariwise,
MYCN promotes the expression of ZNF281 at least in part
by inhibiting the expression of miR-34a. These findings
imply a functional network that includes p73, MYCN and
ZNF281 in NB cells where ZNF281 acts by inhibiting neur-
onal differentiation. Array analysis of NB cells silenced for
ZNF281 expression identified GDNF and NRP2 as two tran-
scriptional targets inhibited by ZNF281. Bioinformatic ana-
lysis of NB datasets indicates that ZNF281 is a prognostic
marker of aggressive, undifferentiated NB. These observa-
tions suggest that ZNF281 is a regulator of cell death during
DNA Damage Response as well as of neuronal differenti-
ation, with relevant implication in cancer. Finally, Melino’s
group identified a novel role for the zinc-finger protein
ZNF281 in regulating the ordered recruitment of the NHEJ
repair factor, XRCC4, at damage sites. ZNF281 is recruited
to DNA lesions within seconds after DNA damage through
a mechanism dependent on poly-ADP ribose polymerase
(PARP) activity and on its DNA binding domain [35].
ZNF281 binds XRCC4 through its zinc-finger domain and
facilitates its recruitment to damaged sites. Consequently,
depletion of ZNF281 impairs the efficiency of the NHEJ re-
pair pathway and decreases cell viability upon DNA damage.
Survival analyses from datasets of commonly occurring hu-
man cancers, show that high levels of ZNF281 correlate with
poor prognosis of patients treated with DNA-damaging
therapies [36]. In conclusion Melino’s lab results define a
late ZNF281-dependent regulatory step of NHEJ complex
assembly at DNA lesions supporting its additional role as
marker for cancer patients’ stratification for therapeutic ap-
proaches in NB treatment.
SESSION IV. Functional immunomics in precision medicine
The recent clinical successes of immune checkpoint
blockade and chimeric antigen receptor T (CAR-T) cell
therapies represent a turning point in cancer immune-
therapy and underscore the importance of understand-
ing basic tumor immunology for successful clinical
translation in treating patients with cancer [37], also rec-
ognized by Nobel Prize awarded in the year 2018 to im-
munologist scientist [38].
This session was dedicated to the usage of immunomics
as a new research tool in systems biology of cellular im-
mune responses in order to ameliorate cancer immuno-
therapy. Currently, cancer genome sequencing and cancer
proteomics are useful for diagnosis and personalized treat-
ment. Analysis of these omics data involves integration of
computation, statistics and systems biology methods. The
amalgam of such methods, which help study interaction of
cancer cells with TME, harnessing immune system for can-
cer therapy or its prevention through vaccines, has led to
the foundation of immune-related genomics and proteo-
mics, namely cancer immunomics [39]. However, we are
still far away from making precise, quick and reliable diag-
nostic and treatment predictions. We need decision sup-
port systems to facilitate diagnosis, tumor evaluation
prediction and assessment of individual profile for making
functional immunomics a personalized clinical reality. Pier-
paolo Correale, director of the oncology unit of the hospital
of Reggio Calabria (Italy), discussed new improvements in
inflammosomics in the prediction of response to immuno-
therapy. In particular, he reported the results of multiple
studies suggesting that that baseline inflammatory status,
occurrence of severe immune-related adverse events
(irAEs) and rise in serum auto-antibodies (AABs), as ANA,
ENA, and ANCA may be a reliable early predictor of re-
sponse in metastatic NSCLC patients treated with nivolu-
mab, a human recombinant IgG-1 addressed to impair the
PD-1/PDL-1 immune-checkpoint [40]. Moreover, Luigi
Buonaguro from IRCSS Fondazione Pascale in Naples
(Italy), discussed on the necessity to identify effective anti-
genic targets for cancer immuno-therapy, especially in he-
patocellular carcinoma (HCC). Indeed, the majority of
HCC patients can be treated only with non-surgical loco-
regional therapies with extremely variable survival rates and
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tumor recurrence in 50 to 80% of patients at 5 years after
treatment. The small kinase inhibitor sorafenib is, together
with the anti-PD1 antibody Pembrolizumab, one of the few
drugs approved for the systemic treatment of advanced
unresectable HCC providing a limited increase in survival.
In this framework, a therapeutic cancer vaccine may repre-
sent an effective strategy to cure HCC. Notably, unlike sev-
eral other cancers, only few cancer vaccine trials for HCC
have been conducted so far with yet modest results, indicat-
ing that improvements in several aspects need to be imple-
mented. In particular, identification of novel specific tumor
antigens, evaluation of delivery systems and combinatorial
strategies to counteract the immuno-suppressive micro-
environment, may result in unprecedented clinical out-
comes with great beneficial effect for HCC patients.
Overall, new technical advancements will foster develop-
ment of ready-to-use chips for easy and rapid screening of
vaccines to improve the outcome of vaccinations. Systems
vaccinology, that is the global approach applied to vaccinol-
ogy from discovery of new antigens to evaluation of vaccine
efficacy, represents the real turning point for the switch
from the “empirical” to the “knowledge-based” age of the
vaccinology, enabling the development of even more suc-
cessful vaccines for preventive as well as therapeutic inter-
vention strategies for cancer immunotherapy [41]. Finally,
Sabrina Arena from University of Turin and Candiolo Can-
cer Institute, Turin (Italy), discussed the clonal cancer evo-
lution as therapeutic target. In particular, the response of
colorectal cancer (CRC) to monoclonal antibodies against
EGFR, such as cetuximab or panitumumab, is often transi-
tory and it is due to the progressive emergence of acquired
resistance. By using a liquid biopsy approach that allows
the detection of emerging resistant cancer clones before re-
lapses are clinically manifest, they discovered that a multi-
step clonal evolution of drug resistant cells underlies the
development of resistance to anti-EGFR antibodies in cells
and CRC patients. Intriguingly, this supports the general
concept that CRC cells likewise exploit adaptive mutability
to evade therapeutic pressure [42]. She further reported
that the generation of new mutations is accelerated when
genes involved in DNA repair pathways are altered and that
the manipulation of the mutational burden can trigger
persistent therapeutic responses. It emerged that the
rational combination of targeted- and immuno-
therapies may restrain tumor evolution and limit the
emergence of drug resistance thus leading to long-term
effective responses.
Closing lecture and remarks
In the closing lecture of the meeting, “Driving the CAR
beyond the checkpoint”, Francesco Marincola from Ref-
uge Biotechnology, Menlo Park (USA), has presented
the most important features of the evolution of anti-
cancer immunological therapy in the direction of
superpersonalized anti-cancer therapy with CAR-T. It is
an established knowledge that cancer cells/tissues have a
constitutive resistance to immunological effectors that
allows them to establish and grow in the host dissemin-
ating in distant organs. Observations in humans based
on transcriptional profiling converge into what we call
an ‘immunologic constant of rejection’ that characterizes
some diseases from organ rejection to autoimmunity
and cancer. This constant includes the coordinate activa-
tion of interferon-stimulated genes and immune effector
functions. Understanding this final effector pathway may
suggest novel strategies for the induction or inhibition of
tissue-specific destruction with therapeutic intent in can-
cer in order to overcome immunological escape [43]. On
this light, recent studies have found that Interferon
gamma-related profile predicts clinical response to im-
munological check point inhibitors [44]. In fact, re-
sponses are dramatic and long lasting but occur in a
subset of tumors and are largely dependent upon the
pre-existing immune contexture of individual cancers.
Available data suggest that three landscapes best define
the TME: immuno-active, immuno-deserted and
immuno-excluded. This trichotomy is observable across
most solid tumors (although the frequency of each land-
scape varies depending on tumor tissue of origin) and is
associated with cancer prognosis and response to check-
point inhibitor therapy (CIT). Various gene signatures
(e.g. Immunological Constant of Rejection and Tumor
Inflammation Signature) that delineate these landscapes
have been described. In an effort to explain the mecha-
nisms of cancer immune responsiveness or resistance to
CIT, several models have been proposed that are loosely
associated with the three landscapes [45]. One of these
models proposes the existence of mechanical (physical
stop of the contact between cancer and T cells), func-
tional (biological or metabolic interactions between
tumor microenvironment cells and immune cells limit-
ing migration, function and/or survival of T cells) and
dynamic barriers (T cell/ cancer cell interaction that
limit the anti-cancer functions of T cells such as im-
munological check points) that hamper the anti-cancer
effects of immune effectors in the tumour tissues. In
order to overcome these resistance mechanisms, CAR-T
cells could represent a good opportunity. Human T cells
engineered to express a chimeric antigen receptor (CAR)
specific for folate receptor-α (FRα) have shown robust
antitumor activity against epithelial cancers in vitro but
not in the clinic because of their inability to persist and
home to tumor in vivo. Therefore, CARs were con-
structed containing a FRα-specific scFv (MOv19)
coupled to the T-cell receptor CD3ζ chain signaling
module alone (MOv19-ζ) or in combination with the
CD137 (4-1BB) costimulatory motif in tandem (MOv19-
BBζ). Transfer of human T cells expressing the
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costimulated MOv19-BBζ CAR mediated tumor regres-
sion in immuno-deficient mice bearing large, established
FRα(+) human cancer. MOv19-BBζ CAR T-cell infusion
mediated tumor regression in models of metastatic in-
traperitoneal, subcutaneous, and lung-involved human
ovarian cancer. Importantly, tumor response was associ-
ated with the selective survival and tumor localization of
human T cells in vivo [46]. In conclusion, the paradox of
immune exclusion could be reverted using superperso-
nalized immunological therapy based upon gene editing
of transplanted immunological effectors.
Conclusion
In conclusion of the 1st international and 32nd Annual
Conference of Italian Association of Cell Cultures (AICC),
it is important to highlight that, based upon the massive
data and results derived from the comprehensive study of
the molecular (both protein and genetic) profile of human
tumours and of the different cellular compartments of the
cancer tissues, a new scenario of intervention and manage-
ment of the cancer disease is emerging. The use of deep se-
quencing and proteomic technologies in the study of
cancers is also becoming attractive and essential in the
diagnostic workflow of cancer patients and the
personalization of therapy, in parallel with the discovery of
new targets both in cancer and micro-environmental cell
components. The organizing committee hopes that this
message reached the over 200 participants, most of them
young researcher, coming from the most important
research and clinical Italian institutions.
As for more than 30 years now, during the meeting
young researchers were awarded for either best posters
or oral presentation and for that we thank the Molecular
and Translational Oncology PhD Program of Magna
Græcia University of Catanzaro and the Journal of Ex-
perimental and Clinical Cancer Research in supporting
AICC conference awards.
Finally, we thank all the participant who guaranteed
success to the AICC Annual Conference.
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